Allied Health & Imaging · Independent exam preparation
AMT Molecular Diagnostics Technologist (MDT): Free Preparation Guide Study Guide
Practise contamination control, PCR interpretation, assay validation and molecular method selection with 60 focused concepts and original AMT MDT study drills.
By CertMedbry · Updated 31 October 2026
Learn to distinguish contamination from inhibition, evaluate molecular assay controls, interpret quantitative results and select methods that can detect the alteration of interest. This selective 60-concept guide follows the four AMT MDT work areas, with greatest emphasis on Diagnostic Methods. The official AMT Certification Competencies and Examination Specifications remains the full examination scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification does this guide cover?
This guide covers the American Medical Technologists Molecular Diagnostics Technologist (MDT) certification. AMT lists MDT separately from Medical Laboratory Scientist and Medical Laboratory Technician. Its scope is molecular laboratory practice; this guide does not substitute another laboratory certification, nursing examination or jurisdictional license for MDT.
Get Certified with AMT · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
How many questions are specified, and how are they distributed?
The official outline specifies 200 questions: I. General Laboratory, 36 questions or 18%; II. General Molecular Diagnostics Theory, 40 or 20%; III. Molecular Laboratory Procedures, 20 or 10%; and IV. Diagnostic Methods, 104 or 52%. The outline does not distinguish scored questions from unscored pretest questions.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
Which blueprint version applies to this guide?
The guide follows AMT's Molecular Diagnostics Technologist Certification Competencies and Examination Specifications PDF bearing ©2020. AMT's certification page and the linked outline were checked on October 31, 2026. The PDF states no separate effective date; its copyright year should not be interpreted as an effective date. The official outline provides the complete competency list.
Get Certified with AMT · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
What duration, item style and passing score apply, and is adaptive behavior established?
The [AMT Candidate Handbook, revised April 2026](https://americanmedtech.org/Portals/0/PDF/ResourceCenter/ApplicationProcess/AMTCandidateHandbook.pdf), allows 3 hours for MDT. AMT examinations use four-option, single-best-answer multiple-choice items. The passing scaled score is 70 on a 0–100 scale; this does not mean 70% correct. Examinations may include unscored pretest items, but an MDT-specific scored/pretest split is not established here. Adaptive behavior remains unresolved. This guide's 20 questions are independent learning exercises.
Get Certified with AMT · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
Where does AMT say candidates can take the examination?
After AMT authorizes testing, its certification page describes scheduling at a Pearson VUE Testing Center or, when offered, a school's Pearson VUE site. School candidates receive scheduling information from their instructor. These sources do not establish remote testing availability for MDT.
How should these concepts and drills be used?
The 60 concepts are allocated 11, 12, 6 and 31 across the four domains, approximately reflecting AMT's 18%, 20%, 10% and 52% weights. The questions and flashcards use allocations of 4, 4, 2 and 10. Use the complete official outline to identify additional competencies beyond this selective guide.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
Independently authored CertMedbry educational material for AMT's Molecular Diagnostics Technologist certification. The questions and flashcards are original learning exercises, not official AMT items or a prediction of examination performance.
Outline used: AMT Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications, ©2020 PDF; linked from AMT's Exam Content page checked 2026-10-13. The PDF gives no separate effective date. The workbook label matches the official AMT exam name; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
I. General Laboratory18%
1.How should laboratory hazards determine PPE selection?
Personal protective equipment creates a barrier between a worker and an identified exposure route. Select gloves, protective clothing and eye or face protection according to splash potential, chemical compatibility and the procedure's biological hazards. A biological safety cabinet and a chemical fume hood control different hazards and are not interchangeable. The discriminating question is what exposure the procedure can generate, rather than whether the specimen appears visibly contaminated.
Apply it
A technologist plans to open several leaking specimen tubes. Assess splash and aerosol hazards before opening them, select appropriate containment and face protection, and replace contaminated gloves before touching shared equipment or clean surfaces.
Common pitfall: Wearing the same gloves throughout the laboratory can spread contamination. Gloves provide a task-specific barrier and do not replace hand hygiene or appropriate containment.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
2.How should a biohazard spill be triaged?
Spill response begins by assessing injury, exposure, aerosol generation, material identity and location. Restrict access and use the laboratory's established response procedure before attempting cleanup. Appropriate disinfectant concentration and contact time depend on the agent, surface and product instructions. Broken glass requires mechanical collection into a suitable sharps container. A spill inside operating containment can require a different response from material released into an occupied room.
Apply it
A specimen tube breaks beside a centrifuge and a coworker has a splash exposure. Initiate the exposure response and secure the area first; then arrange cleanup using the established spill procedure and appropriate protective equipment.
Common pitfall: Immediately wiping a spill with a bare paper towel can spread material and expose the worker. Visible removal alone does not establish effective decontamination.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
3.Which SDS information guides chemical handling?
A safety data sheet identifies chemical hazards and describes handling, storage, protective equipment, first aid and incompatible materials. Consult the sheet for the actual reagent formulation rather than assuming all extraction reagents have identical hazards. The useful decision is whether a proposed handling or disposal step introduces an incompatible reaction or exposure. Manufacturer instructions and the laboratory's chemical hygiene procedures translate those hazards into the specific workflow.
Apply it
An extraction waste bottle contains guanidinium hydrochloride, and a worker proposes adding bleach. QIAGEN warns that its specified guanidinium-containing preparation waste can form highly reactive compounds with bleach. Check the actual reagent's SDS and approved disposal procedure before combining chemicals.
Common pitfall: A reagent's ability to lyse organisms does not establish chemical safety. Treating every extraction waste stream with the same disinfectant can create an additional hazard.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Can I add bleach to the sample preparation waste?
4.How do stability limits affect reagent and specimen acceptance?
Stability describes whether a material retains acceptable properties under specified time, temperature and handling conditions. Expiration, opened-container stability and freeze-thaw limits address different exposures. A reagent or specimen can look normal despite degradation that changes amplification efficiency or target recovery. Acceptance therefore depends on documented storage history and validated limits, with investigation of excursions before use. A passing control does not automatically validate every affected specimen or reagent.
Apply it
A freezer excursion affects an enzyme lot and stored RNA extracts. Review the duration and temperature against separate stability evidence for each material, quarantine affected supplies when necessary, and document the disposition before testing resumes.
Common pitfall: Returning material to its recommended temperature does not reverse degradation. Appearance and nominal expiration date cannot compensate for an undocumented or unacceptable storage excursion.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
5.What distinguishes quality assurance from quality control?
Quality assurance evaluates the entire testing system, including ordering, identification, specimen handling, analysis, reporting and corrective action. Quality control monitors defined analytical processes using controls and acceptance criteria. A run can pass analytical QC while the overall service fails through specimen misidentification or delayed reporting. Distinguish the immediate question of whether an analytical run is acceptable from the broader question of whether the laboratory consistently produces reliable patient results.
Apply it
All amplification controls pass, but an audit finds frequent corrected reports caused by transcription errors. Address report verification and information transfer through quality assurance while maintaining the analytical QC process that evaluates each testing run.
Common pitfall: Passing controls does not prove that every stage of testing worked correctly. Quality assurance must also evaluate errors occurring before analysis and after result generation.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
6.How should a laboratory respond to unacceptable QC?
QC acceptance criteria must be established before patient testing is interpreted. When a required control fails, identify which part of the process it monitors, investigate the cause and determine the affected results. Corrective action should address the failure mechanism, followed by documented evidence that acceptable performance has returned. Repeating controls until one passes, without examining the earlier failure, can conceal a persistent reagent, instrument or procedural problem.
Apply it
A quantitative control shifts above its established acceptance interval after a reagent change. Hold affected results, review preparation and lot comparison data, investigate calibration or reagent effects, and document satisfactory corrective verification before releasing the run.
Common pitfall: A patient result that appears plausible does not override failed required controls. Control interpretation must precede reportability decisions rather than follow the expected clinical story.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
7.How should molecular test information be protected?
Molecular results can contain identifiable health information, including inherited findings relevant to relatives. HIPAA compliance requires authorized access and appropriate safeguards for protected health information. Role-based access, secure communication and verification of recipients reduce unnecessary disclosure. Access should follow legitimate job responsibilities rather than curiosity or personal relationships. The [HHS minimum necessary guidance](https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/minimum-necessary-requirement/index.html) explains limits on uses, disclosures and requests where that standard applies, including its treatment-related exceptions.
Apply it
A coworker asks to see a relative's genetic result despite having no testing or reporting role. Decline informal access and direct the request through the laboratory's authorized patient-information process, preserving both confidentiality and an appropriate audit trail.
Common pitfall: Removing a name alone may leave a report identifiable through other details. Training examples and informal messages still require appropriate handling of protected information.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
8.Why must maintenance be followed by performance verification?
Maintenance reduces equipment deterioration, but completion of a maintenance task does not establish acceptable analytical performance. Verification must examine the functions affected, such as temperature accuracy, optical detection or delivered volume. Trends can reveal gradual deterioration before complete failure. When equipment fails, assess the interval since the last acceptable check and identify potentially affected testing. Equipment records connect maintenance, verification, failures and corrective action into an interpretable history.
Apply it
A thermal cycler receives a temperature-control repair. Before routine testing resumes, verify the affected performance using the laboratory's established checks and assess whether temperature drift could have compromised results generated before the failure was recognized.
Common pitfall: A successful power-on check establishes only limited functionality. It does not demonstrate accurate temperatures, acceptable optics or valid performance for every assay using the instrument.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
9.How does document control prevent procedural drift?
A controlled procedure identifies the approved method, revision, responsibilities, acceptance criteria and required records. Document control ensures personnel can distinguish the current procedure from obsolete copies and that changes receive appropriate review. A procedural change can alter assay performance even when the instrument and target remain unchanged. The key distinction is between following an authorized, evaluated revision and introducing an informal shortcut that has no documented performance basis.
Apply it
A worker suggests halving the extraction elution volume to improve sensitivity. Review the proposed change through the laboratory's change-control process, evaluate its effects on concentration and inhibition, and update the procedure only after appropriate approval and evidence.
Common pitfall: A seemingly small procedural shortcut can change test performance. Familiarity with a method does not authorize undocumented changes to volumes, timings or acceptance criteria.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
10.How is a simple working dilution calculated?
For a simple dilution with compatible units, concentration multiplied by volume is conserved: C1V1 equals C2V2. V2 is the final total volume, not the amount of diluent added. Calculate the stock volume first, then subtract it from the final volume to obtain diluent volume. Check that the requested concentration is below the stock concentration and that the required stock volume can be measured accurately.
Apply it
Prepare 1,000 microliters of a 10 micromolar primer solution from a 100 micromolar stock. Use 100 microliters of stock and 900 microliters of diluent; mixing 100 microliters with 1,000 microliters would produce the wrong concentration.
Common pitfall: Confusing final volume with diluent volume produces systematic concentration errors. Convert units before substituting values and confirm that stock plus diluent equals the intended volume.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
11.How do serial dilution factors combine?
A dilution factor is final volume divided by the volume of original material transferred. Sequential dilution factors multiply because each step acts on the concentration remaining from the previous step. Thorough mixing before each transfer is essential for the calculation to describe the actual material. When reporting a concentration measured after dilution, apply the total dilution factor only if the assay's software has not already made that correction.
Apply it
Dilute an extract by combining 20 microliters with 180 microliters of diluent, then dilute that mixture fivefold. The overall dilution is fiftyfold. A measured concentration of 30 copies per microliter corresponds to 1,500 copies per microliter before dilution.
Common pitfall: Adding successive dilution factors gives the wrong answer. A tenfold dilution followed by a fivefold dilution is fiftyfold, and duplicate software correction creates another error.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
II. General Molecular Diagnostics Theory20%
12.How does DNA polarity determine complementary sequence?
DNA consists of nucleotide chains with sugar-phosphate backbones and complementary bases: adenine pairs with thymine, and guanine pairs with cytosine. The strands run antiparallel, so a sequence written five-prime to three-prime pairs with a strand oriented three-prime to five-prime. When both sequences must be written five-prime to three-prime, use the reverse complement. This distinction is essential for primer orientation and comparison of sequence reads.
Apply it
A target segment is written five-prime AGTC three-prime. Its paired strand is three-prime TCAG five-prime, while the reverse complement written five-prime to three-prime is GACT. Use the orientation required by the sequence-analysis task.
Common pitfall: Writing complementary bases without reversing their order gives the wrong five-prime sequence. Complementarity and reverse complement describe related sequences presented in different orientations.
Deoxyribonucleic Acid (DNA) · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
13.Why do RNA targets require reverse transcription before conventional PCR?
RNA generally contains ribose and uracil, whereas DNA contains deoxyribose and thymine. Transcription produces RNA from a DNA template; translation uses messenger RNA to direct protein synthesis. Conventional DNA polymerase PCR requires a DNA template, so an RNA target is first converted into complementary DNA by reverse transcriptase. The decisive distinction is the nucleic acid being measured: genomic DNA, an RNA genome or a particular expressed transcript.
Apply it
A laboratory wants to measure an expressed fusion transcript rather than merely test genomic DNA. Preserve RNA, perform reverse transcription and amplify the resulting cDNA. Include controls capable of distinguishing transcript signal from contaminating genomic DNA.
Common pitfall: Reverse transcription and real-time detection describe different features. An assay may use either or both, so the abbreviation RT must be interpreted from its context.
Real-Time qRT-PCR · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
14.How can sequence changes alter protein expression or function?
Ribosomes translate messenger RNA in three-base codons, linking amino acids into a polypeptide that folds into a functional structure. A sequence change may preserve an amino acid, substitute one, introduce a stop or alter the reading frame. Splice and regulatory changes can affect transcript abundance or structure without directly changing a coding triplet. The consequence depends on location, transcript context and biological evidence, not simply on detecting a difference.
Apply it
Compare a three-nucleotide deletion within a translated sequence with a one-nucleotide deletion. The three-nucleotide deletion preserves the downstream reading frame, but its exact protein consequence depends on the sequence and codon boundaries. It may delete one amino acid or replace adjacent amino acids with a different junction residue, requiring a protein deletion-insertion description. The one-nucleotide deletion shifts the downstream frame unless another event restores it. Determine the consequence from the relevant transcript rather than assuming an intact codon was removed.
Common pitfall: An in-frame DNA deletion does not automatically mean a simple amino-acid deletion. HGVS distinguishes protein deletion-insertions from substitutions and frameshifts; predicted protein consequences are placed in parentheses.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Mutation · Deletion-Insertion - HGVS Nomenclature
15.Which nuclease activity fits a molecular task?
Endonucleases cleave phosphodiester bonds within a nucleic-acid strand, whereas exonucleases remove nucleotides from an end. Substrate preferences, directionality and recognition requirements differ among enzymes. A restriction endonuclease can generate sequence-dependent fragments, while an exonuclease may remove residual primers under suitable conditions. Distinguish the desired substrate from material that must remain intact, and ensure that enzyme removal or inactivation is compatible with the next analytical step.
Apply it
A preparation contains unwanted single-stranded primers alongside a desired double-stranded product. Select an enzyme with the required substrate preference and validated conditions rather than assuming any nuclease will selectively remove the primers without affecting the product.
Common pitfall: Endonuclease and exonuclease describe cleavage position, not universal substrate specificity. Neither label alone establishes whether an enzyme acts on DNA, RNA or a particular structure.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
16.How does inheritance guide interpretation of a single-gene finding?
Single-gene interpretation requires the disease's inheritance pattern, the number and classification of detected variants, and their arrangement across gene copies. For an autosomal recessive condition, two pathogenic variants generally need to affect opposite homologs to establish biallelic involvement. Two variants on the same homolog do not provide the same evidence. A targeted negative result excludes only the variants and alteration types that the assay can reliably detect.
Apply it
A cystic-fibrosis-related analysis identifies two reportable CFTR variants but does not establish phase. Determine whether they lie on opposite homologs when that distinction is necessary for interpretation, rather than assuming two detected variants demonstrate biallelic disease.
Common pitfall: Counting variants without considering phase, inheritance and classification can overstate a finding. A small targeted panel also cannot exclude every pathogenic alteration in the gene.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
17.What separates chromosome number changes from structural rearrangements?
Numerical abnormalities change chromosome count, while structural abnormalities alter chromosome organization through events such as deletion, duplication, inversion or translocation. Trisomy involves an extra chromosome copy; a balanced rearrangement can change structure without producing net dosage imbalance. Method selection follows the alteration: a copy-number assay may detect a deletion yet miss a balanced translocation. Mosaicism adds another dimension because only a subset of sampled cells may carry the change.
Apply it
A question asks whether a patient has an extra copy of chromosome 21 or a balanced exchange between two chromosomes. Separate dosage from structure before selecting the method; a normal copy-number result cannot resolve every structural possibility.
Common pitfall: Normal total DNA dosage does not establish normal chromosome architecture. Likewise, a specimen's average signal can obscure a low-level abnormal cell population.
Chromosome Abnormalities Fact Sheet · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
18.How are germline and somatic variants distinguished?
A germline variant originates in reproductive lineage and can be transmitted to offspring; a somatic variant arises in other cells and may be restricted to a tissue or clone. A variant detected in tumor material is not automatically somatic because inherited variants can also be present there. Specimen source, tissue distribution and appropriately selected comparison material help distinguish these possibilities. Variant fraction alone is insufficient because purity, copy number and mosaicism affect it.
Apply it
Tumor sequencing detects a variant near a fifty-percent allele fraction. Consider inherited and acquired explanations, review tumor purity and copy-number findings, and use an appropriate validated comparison strategy before assigning germline status or implications for relatives.
Common pitfall: A fifty-percent variant fraction does not prove inheritance. Tumor admixture, loss of heterozygosity and copy-number changes can produce misleading fractions in either direction.
Mutation · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
19.How does organism biology shape infectious molecular testing?
Bacteria are prokaryotes, while fungi and parasites are eukaryotic organisms; viruses depend on host cells and may have DNA or RNA genomes. These differences influence target selection, extraction and amplification requirements. Cytomegalovirus (CMV) can cause serious disease in immunocompromised transplant recipients, and Epstein–Barr virus (EBV) is associated with post-transplant lymphoproliferative disorder. Both are DNA viruses. A positive nucleic-acid result establishes detection in the tested specimen, while tissue-invasive disease or a lymphoproliferative disorder requires additional clinical and diagnostic evidence. See [CDC CMV guidance](https://www.cdc.gov/infection-control/hcp/healthcare-personnel-epidemiology-control/cytomegalovirus.html) and [CDC EBV guidance](https://www.cdc.gov/epstein-barr/hcp/clinical-overview/index.html).
Apply it
A transplant recipient has detectable CMV DNA in blood. Use the validated quantitative assay and comparable serial measurements to assess changes in DNAemia, alongside symptoms and organ-specific findings. Blood detection alone does not establish CMV tissue disease. Likewise, detecting EBV DNA does not by itself diagnose post-transplant lymphoproliferative disorder; evaluate the relevant clinical and tissue evidence.
Common pitfall: No universal CMV or EBV viral-load threshold establishes disease across specimen types, assays and transplant settings. Organism identity and specimen context matter as much as detection.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
20.Why are viral detection, quantification and genotyping different tasks?
Detection asks whether a defined viral target is present, quantification estimates its amount and genotyping characterizes selected sequence differences. A genotyping assay may require more target material or different genomic regions than a sensitive detection assay. Its conclusions are limited to the regions and variant mixtures it can resolve. Sequence identity can inform classification or resistance interpretation, but a negative genotype result does not necessarily contradict a positive detection result.
Apply it
A specimen is positive by a sensitive viral detection assay but fails genotyping at a low target concentration. Review the genotype assay's input requirements and analytical limits before concluding that the original positive was erroneous or that no relevant variant exists.
Common pitfall: A successful detection assay does not guarantee successful sequencing. Genotyping failure and absence of a particular resistance-associated sequence are different analytical conclusions.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
21.How does mecA support MRSA identification and resistance reporting?
The mecA gene encodes PBP2a, an altered penicillin-binding protein with reduced affinity for beta-lactam antibiotics. Detecting this resistance mechanism differs from measuring bacterial growth during susceptibility testing. A mecA-only assay can miss mecC-mediated resistance and other uncommon resistance phenotypes. CDC states that an identified S. aureus isolate positive for mecA or PBP2a, or resistant by a recommended phenotypic method, should be reported as methicillin/oxacillin resistant. A negative mecA-only result therefore does not override confirmed resistance established by a recommended phenotypic method.
Apply it
An identified S. aureus isolate is mecA-negative but resistant by cefoxitin disk diffusion. Investigate organism identification, culture purity, controls, technical validity and assay target coverage. If the identification and resistant phenotype are confirmed, report methicillin/oxacillin resistance despite the negative mecA result; identifying the alternative mechanism is a separate investigative objective.
Common pitfall: Oxacillin disk diffusion is unreliable for S. aureus and should not be substituted for a recommended method. In mixed specimens, detecting mecA alone also does not establish which organism carries the gene.
Laboratory Testing for Methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
22.How do oncogenic fusions connect diagnosis and targeted therapy?
An oncogenic rearrangement can join portions of two genes and create an abnormal protein with persistent signaling activity. BCR::ABL1 is a hallmark example involving dysregulated tyrosine kinase activity, described in the [NCI chronic myeloid leukemia treatment summary](https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq). Molecular methods may detect the DNA rearrangement, an RNA fusion transcript or a chromosome-level signal pattern, each with different coverage. Treatment response and resistance can depend on the specific alteration and pathway, so detecting a gene name alone is insufficient for complete interpretation.
Apply it
A follow-up assay targets one BCR::ABL1 transcript junction. Before using it to monitor a newly diagnosed specimen, confirm that the patient's fusion transcript is covered; a valid assay for one junction may miss another expressed junction.
Common pitfall: A fusion assay is not automatically comprehensive because it targets both gene names. Breakpoint, transcript and specimen requirements determine what the method can detect.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
23.How should a pharmacogenomic result be interpreted?
Pharmacogenomics connects measured genetic variation to predicted function and then to a drug-specific effect. For example, CYP2D6 *4 is a no-function allele. A reliably resolved *4/*4 diplotype predicts a CYP2D6 poor-metabolizer phenotype. Because CYP2D6 contributes to paroxetine metabolism, poor metabolism can increase paroxetine exposure and the probability of concentration-related adverse effects. This sequence of interpretation—alleles, predicted enzyme function, drug consequence—is described in the [2023 CPIC serotonin reuptake inhibitor guideline](https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427.pdf). The implication is drug-specific; reduced metabolism does not affect every drug in the same way.
Apply it
A CYP2D6 assay resolves two *4 alleles and adequately assesses relevant copy number and structural variation. Assign the supported poor-metabolizer phenotype, then connect it to reduced paroxetine metabolism and potentially higher exposure. If the assay instead detects selected *4-associated variants without resolving copy number or complex alleles, qualify the allele and phenotype assignment rather than claiming a complete diplotype.
Common pitfall: Absence of tested variants does not guarantee normal function. Copy number, hybrid alleles, phase and untested variation can prevent complete allele resolution; concomitant drugs can also alter observed enzyme activity.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
III. Molecular Laboratory Procedures10%
24.Why does unidirectional workflow reduce carryover contamination?
Amplified products can contain enormous numbers of target copies and contaminate subsequent reactions. Physical separation and movement from clean reagent preparation toward specimen processing and amplification reduce transfer back into clean areas. Dedicated equipment, protective clothing and supplies support that separation. Molecular contamination may create a false-positive result without viable organisms being present, whereas biological contamination can also create an exposure hazard. Both require controls suited to their distinct consequences.
Apply it
A worker finishes opening amplified tubes and then needs to prepare tomorrow's master mix. Follow the established clean-area reentry procedure, including appropriate changes of protective items and equipment, rather than carrying post-amplification materials into reagent preparation.
Common pitfall: A closed amplification instrument does not eliminate all contamination risks. Specimen handling, stock preparation and movement of contaminated gloves or equipment still require controlled workflow.
False-Positive Investigation Toolkit · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
25.How is RNA protected during molecular preparation?
RNA integrity depends on controlling RNase exposure and preserving specimens under validated conditions. RNases can be introduced through hands, surfaces, reagents and equipment; an apparently clean bench is not necessarily RNase-free. Use suitable consumables, designated preparation practices and appropriate preservation. Degradation may disproportionately affect longer targets or distort expression measurements. RNA quantity alone cannot establish intact, amplifiable material, so assess quality using measures appropriate to the intended assay.
Apply it
Two extracts have similar RNA concentrations, but one produces poor amplification of a longer transcript. Review preservation, handling and integrity evidence before increasing input, because adding more degraded material may not restore the missing amplifiable target.
Common pitfall: A high RNA concentration does not prove good integrity. RNase-free handling and validated storage remain necessary even when extraction yield appears adequate.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · cms_042380.pdf
26.Which specimen features determine molecular test acceptability?
Specimen acceptance connects identity, specimen type, container, quantity, transport and preservation to the validated assay. An analytically detectable target cannot compensate for uncertain patient identity. Matrix effects and collection additives may inhibit testing or change recovery. Aliquoting can reduce repeated handling and freeze-thaw exposure, but aliquots require traceable identification. Rejection and exception criteria should distinguish remediable handling issues from defects that prevent a reliable patient-specific result.
Apply it
A well-preserved swab arrives with a label that does not match the requisition. Resolve the identity discrepancy through the established specimen policy before testing; successful amplification would not establish which patient should receive the result.
Common pitfall: Acceptability cannot be judged from volume alone. Correct identification and a validated specimen-container combination remain necessary even when sufficient material is available for analysis.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
27.How does pipette selection influence molecular assay precision?
Delivered volume depends on selecting a pipette within its specified operating range and using consistent aspiration and dispensing technique. Tip fit, immersion depth, liquid properties and mixing can affect delivery. Very small transfers magnify relative error and may justify a validated intermediate dilution. Calibration evaluates volume performance, while good technique controls how that performance is realized during testing. Filtered tips help reduce carryover but do not correct poor volume selection.
Apply it
A setup requires 0.5 microliters of stock, below the available pipette's specified range. Prepare a suitable validated intermediate dilution and transfer a measurable volume, preserving the required final concentration while reducing avoidable volumetric uncertainty.
Common pitfall: Setting a larger pipette below its rated minimum does not make it accurate. A displayed volume is not evidence that the instrument can deliver it reliably.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · cms_042380.pdf
28.How are nucleic-acid quantity, purity and integrity distinguished?
Quantity estimates how much nucleic acid is present, purity assesses contamination and integrity describes molecular preservation or fragmentation. Absorbance can reflect several UV-absorbing substances, while fluorescent assays can offer greater selectivity for particular nucleic-acid forms. Neither measurement alone proves successful amplification. An extract may have adequate mass yet contain inhibitors or fragments too short for the target. Choose quality measures that address the assay's input requirements and failure risks.
Apply it
An extract has a high absorbance-based concentration but a much lower double-stranded-DNA fluorescence result. Investigate contaminants or other nucleic acids, then evaluate usable input and amplification behavior instead of treating the larger concentration estimate as automatically correct.
Common pitfall: A favorable purity ratio does not demonstrate intact target or absence of every inhibitor. Concentration, purity, integrity and functional amplifiability answer different questions.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
29.How do performance establishment, verification and external assessment differ?
A laboratory-developed testing context involves an in vitro diagnostic test designed, manufactured and used within a single laboratory. Under 42 CFR 493.1253, an unmodified FDA-cleared or approved system requires local verification of accuracy, precision and reportable range, plus verification that the manufacturer's reference intervals suit the laboratory's population. Modified systems and in-house methods require establishment of performance specifications before patient reporting, including accuracy, precision, analytical sensitivity, analytical specificity with interfering substances, reportable range and reference intervals as applicable. Routine QC and external assessment then monitor continuing performance. CLIA laboratory obligations are distinct from FDA device oversight: [FDA reports](https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests) that its 2024 LDT rule was vacated and the regulatory text reverted in 2025.
Apply it
For an in-house plasma assay, establish performance for the intended use before reporting patients; a later tissue claim needs supporting evaluation. Under [42 CFR 493.1236](https://www.ecfr.gov/current/title-42/section-493.1236), verify accuracy at least twice annually for tests outside the regulated PT analytes or when compatible PT samples are unavailable from a CMS-approved program. Under [42 CFR 493.801](https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-H/section-493.801), test PT samples through routine patient-testing processes, do not communicate PT results with other laboratories before the reporting deadline, and do not refer PT samples to another laboratory for analysis.
Common pitfall: A correct external challenge does not replace initial performance establishment or validate an additional specimen type. FDA's LDT rule vacatur did not remove CLIA performance, quality-system or PT obligations.
Federal Register :: Request Access · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
IV. Diagnostic Methods52%
30.How should primers define a specific amplification target?
PCR primers bind opposite template strands with their three-prime ends oriented toward the region to be amplified. Specificity depends on target complementarity, sequence uniqueness and avoidance of problematic self-complementarity or cross-homology. Secondary structure and variants within binding sites can impair amplification. Assess both primers as a pair because acceptable individual sequences may still interact or amplify an unintended locus. A correct gene label does not establish specificity for the intended sequence.
Apply it
A candidate primer pair matches the target gene but also matches a closely related pseudogene. Redesign or otherwise establish discrimination using appropriate sequence features and validation material before interpreting positive amplification as evidence from the intended locus.
Common pitfall: A database match to the desired target is insufficient if equally compatible unintended sites exist. Three-prime complementarity and homologous regions deserve particular attention.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Deoxyribonucleic Acid (DNA) · MAN0012618_Guidelines_Primer_Design_UG.pdf
31.How can primer melting temperature be estimated, and how does it inform annealing optimization?
Primer melting temperature, Tm, describes duplex melting under specified conditions; it is not automatically the PCR annealing temperature. Thermo Fisher provides the approximate equation Tm = 4(G+C) + 2(A+T) for primers shorter than 25 nucleotides, where each letter represents its base count. A 20-nucleotide primer containing 10 G/C bases and 10 A/T bases therefore has an estimated Tm of (4 × 10) + (2 × 10) = 60°C. Count the template-complementary portion when a primer includes a noncomplementary extension. This simple estimate does not fully account for neighboring-base interactions or solution conditions.
Apply it
Use the 60°C estimate as preliminary design information, then model the primer pair under the intended salt, magnesium and oligonucleotide conditions. Evaluate an annealing-temperature gradient experimentally. If lower temperatures produce several bands and a higher temperature produces the expected-size band, assess that condition with positive, negative and low-level samples to establish specificity without sacrificing necessary sensitivity.
Common pitfall: Do not prescribe a 60°C annealing step solely because the approximate Tm is 60°C. Excessive stringency can suppress the target, while permissive conditions or increased primer and magnesium concentrations can promote nonspecific amplification. Strong total fluorescence or a bright band alone does not establish specificity.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · MAN0012618_Guidelines_Primer_Design_UG.pdf
32.How should a master mix be calculated and prepared?
A master mix combines shared reagents to reduce repeated pipetting and improve consistency across reactions. Calculate the number of reactions including specimens, controls and a justified allowance for handling loss. Reconstitute stocks using the specified solvent and volume, then calculate each component's final reaction concentration. Adding template changes total volume and must be included. Mixing and appropriate handling are necessary because a correct spreadsheet cannot compensate for incomplete reagent resuspension.
Apply it
A run includes 18 specimens and three controls. If the approved setup uses a ten-percent preparation allowance, make enough shared mix for 23.1 reaction equivalents or an appropriate practical round-up, while dispensing the validated volume into each actual reaction.
Common pitfall: Preparation overage supplies extra mix; it does not justify increasing the volume placed in each well. Control wells and template volume must remain in the calculation.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · cms_042380.pdf
33.Which controls distinguish contamination, extraction failure and inhibition?
A no-template control monitors contamination introduced into the amplification setup, while an extraction blank also passes through extraction. A positive control challenges target detection. A suitably designed internal control can reveal extraction failure or amplification inhibition, depending on when it is added and what it measures. Interpret failures according to that placement. A clean no-template control does not exclude specimen-specific inhibition, and a strong positive control may not reveal loss of low-level sensitivity.
Apply it
A specimen is target-negative and its internal amplification control fails, while the positive control and no-template control are acceptable. Investigate the specimen's extraction or inhibition status before reporting a valid negative, using the control's actual design to guide troubleshooting. The [archived CDC wastewater methods page](https://archive.cdc.gov/www_cdc_gov/nwss/testing.html) also illustrates inhibition assessment and negative controls in environmental surveillance; its context does not establish clinical assay cutoffs.
Common pitfall: Calling every control an extraction control obscures its coverage. A control added after extraction cannot demonstrate recovery through the extraction steps it never experienced.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · False-Positive Investigation Toolkit
34.How should borderline molecular signals be evaluated?
A result cutoff converts analytical evidence into a defined reporting category using validated criteria. Near the detection limit, low-copy sampling can produce variable replicate detection even without a procedural error. Review curve quality, controls, specimen history and the assay's established repeat or interpretation rules. A late signal is neither automatically contamination nor automatically a valid positive. Its meaning depends on assay-specific validation rather than a universal cycle-threshold value.
Apply it
One replicate produces a late sigmoidal signal and another is undetected. Apply the assay's established low-level interpretation procedure and review controls and contamination context; do not create a new cutoff after seeing this specimen's result.
Common pitfall: A universal cycle number cannot classify every assay. Extending cycling or selectively repeating until a preferred result appears can invalidate established interpretation criteria.
Real-Time qRT-PCR · False-Positive Investigation Toolkit · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
35.How do calibrators support quantitative reporting?
Calibrators assign a relationship between assay signal and known target quantities. Their values, units, matrix and traceability affect the meaning of reported concentrations. Controls independently monitor whether the calibrated system performs acceptably; they are not interchangeable with calibrators. Quantitative results also depend on extraction, input and dilution calculations. Compare longitudinal values cautiously when methods or reporting units change because equal numerical values do not necessarily represent equivalent measurements across systems.
Apply it
A laboratory changes from copies per milliliter to international units per milliliter. Establish the appropriate method-specific relationship and reporting implementation rather than relabeling historical numbers or assuming that one copy always equals one international unit.
Common pitfall: A calibration curve that fits its own standards does not independently prove patient-sample accuracy. Controls and matrix-appropriate validation are needed to evaluate the calibrated system.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Real-Time qRT-PCR · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
36.How does a standard curve reveal PCR performance?
A quantitative PCR standard curve commonly plots cycle threshold against the base-10 logarithm of starting target quantity. More starting target should cross the threshold earlier, producing a negative slope. Fractional amplification efficiency is E = 10^(−1/slope) − 1; multiply by 100 to express efficiency as a percentage. A slope near −3.32 corresponds to approximately 100% efficiency, or doubling per cycle. Linearity must be evaluated across the intended interval; a good fit alone cannot exclude systematic bias or inhibition.
Apply it
Tenfold standards show evenly spaced thresholds in the middle of the range, but the highest standard deviates. Investigate inhibition, preparation or saturation and establish the supported quantitative interval rather than extrapolating a straight line through an unreliable endpoint.
Common pitfall: A high correlation coefficient does not prove acceptable calibration. Incorrect assigned concentrations, shared dilution errors or a restricted range can still produce an impressive fit.
Real-Time qRT-PCR · cms_042380.pdf · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
37.How do sensitivity, specificity and predictive value differ?
Clinical sensitivity is the proportion of affected individuals testing positive, while clinical specificity is the proportion of unaffected individuals testing negative under the defined comparison. Positive predictive value is the proportion of positive results corresponding to the condition and depends on prevalence, sensitivity and specificity. Analytical sensitivity needs an assay-specific definition: infectious or quantitative assays often describe detection at low target concentrations, whereas genetic assays may describe the proportion of specimens with known variants correctly detected. Analytical specificity addresses discrimination from related targets, cross-reactivity and interference. State the definition, variant classes and denominator rather than treating analytical sensitivity as universally synonymous with detection limit.
Apply it
For a viral assay, evaluate low-concentration detection using replicate challenges at defined concentrations. For a genetic assay, report correct detection among known variant-positive specimens and distinguish tested classes such as substitutions, small deletions and copy-number changes. Separately, moving a clinical test to a lower-prevalence population generally lowers positive predictive value when sensitivity and specificity remain unchanged.
Common pitfall: A low concentration limit does not establish comprehensive variant detection, and a high detection proportion in selected variant-positive specimens does not establish sensitivity for untested classes. Clinical and analytical denominators answer different questions.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
38.How should a validation study connect performance claims to evidence?
Define intended use, specimen types, reportable targets and alteration classes, then establish acceptance criteria before evaluating data. Accuracy requires comparison with appropriate reference materials, characterized specimens or a suitable comparison method. Precision requires repeated measurements across relevant conditions such as days, operators and runs. Detection capability requires low-concentration challenges or defined variant-positive specimens, as appropriate. Specificity requires relevant cross-reactivity and interference challenges. Quantitative range requires materials spanning the proposed interval with acceptable bias and precision. Establish or verify reference intervals where applicable. These characteristics reflect 42 CFR 493.1253; the particular materials, replication and study layout must be justified for the assay.
Apply it
For an illustrative in-house viral-load study, compare characterized plasma specimens with assigned values or a suitable method; repeat low, middle and high materials across days and operators; challenge concentrations near the proposed detection limit; test related organisms and expected interferents; and examine supported concentrations across the proposed reporting range. Predefine acceptable agreement, variation and detection performance. A tight cluster near 800 copies/mL for material assigned 1,000 supports precision but raises an accuracy concern. These study choices illustrate implementation rather than a universally mandated sample count or design.
Common pitfall: One successful comparison or a high correlation coefficient cannot establish every performance characteristic. Resolve failures against predefined criteria and limit claims to supported specimen types, concentrations and variant classes.
Federal Register :: Request Access · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
39.How do the three PCR stages generate selective amplification?
PCR cycles separate DNA strands by denaturation, allow primers to bind during annealing and extend those primers using a polymerase. The primer pair defines the region capable of repeated amplification. Under ideal conditions, target copies double each cycle, but practical reactions lose efficiency and eventually plateau. Endpoint product quantity therefore does not reliably preserve starting-template differences. Successful amplification also requires suitable template, nucleotides, buffer, magnesium and an active polymerase.
Apply it
A qualitative PCR produces the expected band in a positive specimen, but a second specimen's brighter endpoint band is interpreted as twice the initial target. Reject that quantitative inference because endpoint intensity can reflect plateau behavior and reaction differences.
Common pitfall: PCR amplifies the region bounded by compatible primers, not an entire organism or chromosome. Product presence must still be evaluated for specificity and control acceptability.
Real-Time qRT-PCR · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · cms_042380.pdf
40.How does a TaqMan hydrolysis probe produce fluorescence?
A TaqMan probe binds within the amplified region and carries a fluorescent reporter and quencher. While intact, their proximity suppresses reporter fluorescence. During extension, the polymerase's five-prime nuclease activity cleaves a bound probe, separating reporter from quencher and increasing detectable signal. Signal therefore depends on compatible primer amplification and probe hybridization. This differs from a dye that fluoresces upon binding double-stranded DNA without recognizing a specific internal sequence.
Apply it
An assay uses the correct primers but a specimen variant disrupts probe binding. Product may be generated without the expected fluorescent signal. Consider probe-site variation when controls pass yet an independently supported target repeatedly fails detection.
Common pitfall: The probe does not replace the primers or initiate target amplification. Its additional sequence recognition improves discrimination but also introduces another binding site vulnerable to variation.
Real-Time qRT-PCR · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
41.What can a melting curve reveal about amplification products?
As double-stranded DNA melts with increasing temperature, a DNA-binding dye loses fluorescence. Plotting the rate of fluorescence change can reveal peaks associated with products of different melting behavior. Unexpected peaks can suggest nonspecific products or primer dimers, but melting temperature alone does not establish exact sequence identity. Sequence, length and solution conditions influence melting. Interpret curves against validated product behavior and appropriate controls rather than treating every peak as the intended target.
Apply it
A dye-based assay shows the expected target peak in specimens but a separate lower-temperature peak in the no-template control. Investigate primer-dimer formation and its effect on interpretation instead of automatically classifying that control peak as target contamination.
Common pitfall: One melt peak does not prove a unique correct sequence. Different products can have similar melting behavior, and minor products may be difficult to resolve.
Real-Time qRT-PCR · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · cms_042380.pdf
42.When can cycle-threshold differences estimate target ratios?
Cycle threshold marks when fluorescence crosses a defined threshold above background. Within the same validated assay, earlier crossing generally indicates more starting target. If amplification doubles each cycle and relevant conditions are equivalent, a one-cycle difference corresponds to approximately a twofold target difference, and a 3.32-cycle difference to approximately tenfold. Extraction, inhibition, input and threshold settings can disturb this relationship. Thresholds from unrelated assays should not be treated as interchangeable quantitative measurements.
Apply it
Two equally processed samples in the same assay cross at cycles 23 and 26 with approximately doubling efficiency. The cycle-23 sample has about eight times the starting target, provided both measurements fall within the validated comparison range.
Common pitfall: A lower threshold can reflect more input or less inhibition rather than a biological increase. Cross-platform cycle values require more than numerical comparison.
Real-Time qRT-PCR · cms_042380.pdf · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
43.How does allele-specific PCR discriminate a selected variant?
Allele-specific PCR uses primer-template discrimination, often at a primer's three-prime end, to favor amplification of one sequence over another. The strength of discrimination depends on mismatch type, enzyme and reaction conditions. Appropriate genotype controls and an amplification control help distinguish the tested allele's absence from technical failure. This is a targeted approach: successful detection of one selected change does not characterize all variation in the gene or nearby binding sites.
Apply it
A variant-specific reaction is negative while a separate locus amplification control is positive. Interpret this as absence of the tested detectable allele within validated limits, rather than declaring the entire gene normal or excluding every possible variant.
Common pitfall: A mismatch does not always block polymerase completely. Analytical validation must establish discrimination, especially when a small variant fraction is mixed with abundant reference sequence.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
44.Why must multiplex PCR be evaluated as a combined reaction?
Multiplex PCR amplifies multiple targets in one reaction using several primer pairs and, when applicable, distinct detection channels. Targets can compete for reagents, and primers can interact with one another. A strong target may impair detection of a weaker one even when each single-target assay performs well alone. Validation must evaluate relevant combinations, low-level targets, cross-reactivity and signal separation. Individual assay success does not establish combined assay performance.
Apply it
A respiratory multiplex detects each organism separately, but a low-level target disappears when another target is abundant. Investigate competition using mixed-target specimens and adjust or qualify the assay before claiming equivalent sensitivity in coinfected samples.
Common pitfall: Adding independently validated primer pairs does not automatically create a validated multiplex. Competition and cross-channel effects emerge from the combined reaction and detection system.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · cms_042380.pdf
45.Why does nested PCR increase contamination risk?
Nested PCR uses an initial amplification followed by another amplification with primers internal to the first product. Requiring compatible inner and outer targets can improve specificity and sensitivity. However, transferring first-round product introduces highly concentrated amplicon into a second setup, creating substantial carryover risk. Physical separation, controlled handling and suitable negative controls are therefore critical. Greater analytical sensitivity can also amplify contamination that would have been undetectable by the first round alone.
Apply it
A nested assay develops sporadic positives after workers transfer first-round products near clean setup supplies. Investigate amplicon movement, review negative controls and restore separated workflow before interpreting weak second-round signals as true specimen findings.
Common pitfall: Two rounds of amplification do not make a result inherently trustworthy. Nested specificity cannot compensate for introducing the correct target amplicon as contamination.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · False-Positive Investigation Toolkit
46.What separates target amplification from signal amplification?
Target amplification creates additional copies of the nucleic-acid target, as PCR does. Signal amplification increases the detectable signal associated with captured target without necessarily copying that target. Branched-DNA methods assemble probe structures that support multiple signal-generating labels and are signal-amplification methods rather than PCR variants. This distinction helps predict reagent requirements, contamination concerns and interpretation. Other target-amplification methods may use different enzymes or constant-temperature chemistry instead of PCR thermal cycling.
Apply it
An assay captures target RNA and builds branched probe structures bearing many labels, without polymerase-driven target copying. Classify it as signal amplification and evaluate its calibration and controls according to that mechanism rather than expecting PCR cycling behavior.
Common pitfall: Every increasing molecular signal is not PCR. Branched-DNA signal amplification and reverse-transcription PCR can both analyze RNA while using fundamentally different amplification mechanisms.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
47.How does microRNA regulate gene expression?
MicroRNAs are short regulatory RNAs that associate with protein complexes and recognize target messenger RNAs through sequence interactions. They can reduce protein production by promoting transcript degradation or repressing translation. Measuring a microRNA therefore measures a regulatory RNA species, not a protein-coding transcript. Their short length creates distinctive extraction and assay-design challenges. Methods optimized for longer RNA molecules may recover or measure microRNAs differently, making preparation and normalization important analytical considerations.
Apply it
A laboratory extends a long-RNA extraction workflow to a microRNA assay. Evaluate recovery of the short RNA species and suitable normalization rather than assuming that acceptable total RNA yield demonstrates reliable microRNA measurement in the new workflow.
Common pitfall: MicroRNA abundance is not a direct measurement of its target protein. Regulatory effects depend on biological context, and extraction performance can differ from longer transcripts.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · cms_042380.pdf
48.When is a housekeeping gene suitable for normalization?
A reference or housekeeping gene can normalize expression measurements for differences in input or processing only if its expression is sufficiently stable in the samples being compared. Stability is contextual: tissue composition, treatment and disease can alter commonly used reference genes. Relative quantification also depends on suitable amplification performance. A reference gene is a measured comparator, not an automatic guarantee that biological and technical variation have been removed.
Apply it
An experimental treatment changes the proposed reference transcript as well as the target transcript. Evaluate alternative stable reference genes before calculating relative expression, because normalizing to a treatment-responsive comparator can conceal or reverse the apparent target change.
Common pitfall: A familiar reference-gene name does not establish stability in every tissue or condition. Detectable expression and stable expression are different requirements for meaningful normalization.
Real-Time qRT-PCR · cms_042380.pdf · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
49.How should variant references be matched to a laboratory finding?
Variant interpretation begins with an unambiguous description using the appropriate gene, reference sequence, transcript and genomic build when relevant. The same alteration can have different coordinates or consequences across transcripts, and similar names can describe different changes. Evaluate primary evidence, population information, functional findings and disease context rather than copying a classification without review. Document the reference version and evidence used so that another reviewer can reconstruct the interpretation.
Apply it
A published variant appears to differ from a laboratory finding by one coordinate. Compare reference transcripts, numbering conventions and strand orientation before treating the records as different alterations or using the publication to support a classification.
Common pitfall: A matching amino-acid label alone may not identify the same nucleotide change or transcript. Database classifications also require context, evidence review and attention to updates.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Deletion-Insertion - HGVS Nomenclature
50.How should Sanger traces and strand orientation be reviewed?
Sanger sequencing separates terminated fragments to infer nucleotide order from fluorescent signals. Review peak separation, background, read quality and the usable sequence interval before calling variants. A heterozygous single-nucleotide change may produce overlapping peaks at one position, while an insertion or deletion mixture can disrupt downstream alignment. Reverse reads must be reverse-complemented for comparison with a forward reference. Poor-quality ends should not support confident calls simply because software assigned bases.
Apply it
A forward trace suggests a variant near a noisy read end, while a good reverse read covers that position. Align the reverse complement to the correct reference and evaluate the reliable signal rather than reporting the uncertain forward base alone.
Common pitfall: An automated base call is not a substitute for trace review. Strand-orientation errors and low-quality terminal sequence can create apparent variants that are not supported.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Deoxyribonucleic Acid (DNA) · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
51.How does the NGS workflow connect specimens to variant calls?
Next-generation sequencing combines nucleic-acid preparation, library construction, sequencing and computational analysis. Libraries contain fragments with adapters and often sample indexes; analysis assigns reads, evaluates quality, aligns or assembles sequence and identifies supported alterations. Errors can originate at any stage, including sample mix-up, library bias and incorrect analysis settings. Acceptance criteria must therefore cover both wet-bench and computational performance. Large data volume does not independently establish sample identity or reliable variant detection.
Apply it
An NGS run meets total-read targets, but one sample has poor on-target recovery. Assess that sample's coverage and library metrics separately rather than accepting it because the pooled run produced enough reads overall.
Common pitfall: Run-level success can hide sample-level or region-level failure. Sequencing acceptance must connect usable data to the actual reportable targets and validated alteration classes.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Characterizing sensitivity and coverage of clinical WGS as a diagnostic test for genetic disorders · Client Challenge
52.Why does a negative exome or genome result require coverage review?
Whole-exome sequencing emphasizes coding regions, whereas whole-genome sequencing samples a broader genomic space. Neither guarantees adequate detection at every position or for every alteration class. Read depth, mapping ambiguity, sequence composition and the analysis pipeline influence sensitivity. Average coverage can conceal poorly covered clinically relevant regions. A negative result is strongest where the assay has demonstrated adequate coverage and validated detection; uncovered or difficult regions remain limitations rather than evidence of normal sequence.
Apply it
A genome assay has high average depth, but a clinically relevant exon contains few uniquely mapped reads. Review the region-specific limitation and consider an appropriate supplementary method within the testing strategy instead of treating the genome result as complete exclusion.
Common pitfall: Whole genome describes broad scope, not perfect completeness. High average depth cannot compensate for a specific region with inadequate usable reads or an unsupported variant class.
Characterizing sensitivity and coverage of clinical WGS as a diagnostic test for genetic disorders · Client Challenge · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
53.How should bioinformatics evidence support an NGS variant call?
A variant call should be evaluated using read depth, base and mapping quality, strand representation, allele fraction and local sequence context within a validated pipeline. Repetitive regions or nearby indels can produce misleading alignments. Filtering reduces artifacts but can also remove true variants outside assumed patterns. Software and reference changes can alter calls, so controlled versions and appropriate performance evaluation matter. Numerical support is meaningful only when the underlying reads are informative.
Apply it
A candidate variant has many supporting reads, but nearly all have low mapping quality in a homologous region. Investigate alignment ambiguity and the assay's validated approach to that locus before accepting the apparent depth as strong evidence.
Common pitfall: A large raw read count can be misleading when reads are duplicated or ambiguously aligned. More observations do not rescue a shared systematic mapping error.
Characterizing sensitivity and coverage of clinical WGS as a diagnostic test for genetic disorders · Client Challenge · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
54.Which chromosome changes can a copy-number microarray detect?
A genomic copy-number microarray compares hybridization signals across many probes to identify relative gains or losses of genomic material. Detection depends on probe coverage, alteration size, signal quality and mosaic fraction. A balanced rearrangement may escape detection because no net dosage change occurs. Likewise, most single-nucleotide substitutions are outside a copy-number array's purpose. Select the method according to the suspected alteration rather than assuming genome-wide probe distribution means every genetic change is detectable.
Apply it
A specimen has a normal copy-number array, but the clinical question concerns a balanced translocation. Use a structural-rearrangement strategy appropriate to that question rather than treating the array result as exclusion of the suspected chromosome architecture.
Common pitfall: Genome-wide dosage assessment is not whole-genome sequencing. A normal array cannot exclude every sequence variant, balanced rearrangement or low-level mosaic abnormality.
Chromosome Abnormalities Fact Sheet · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
55.How do SNP arrays differ from expression arrays?
SNP arrays examine selected genomic positions and can provide allele-pattern information in addition to copy-number signals. Such patterns can identify regions of absent heterozygosity, which require context for interpretation. Expression arrays instead measure relative abundance of represented RNA transcripts after suitable preparation. Probe content limits both approaches, and hybridization specificity affects signal interpretation. Distinguish a genomic allele-pattern question from a transcript-expression question before choosing an array and analysis workflow.
Apply it
A laboratory needs to investigate a long region lacking heterozygous SNP calls despite normal dosage. Review SNP allele-pattern data and specimen context; an expression array would address transcript abundance rather than the genomic allele distribution of interest.
Common pitfall: Absent heterozygosity does not itself establish a specific inheritance mechanism. Expression differences also cannot be interpreted as DNA copy-number changes without appropriate genomic evidence.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications · Chromosome Abnormalities Fact Sheet
56.Which FISH probe design answers a rearrangement question?
FISH uses fluorescent probes that hybridize to complementary DNA in cells or chromosome preparations. Enumeration probes address copy number; dual-fusion designs investigate a specified gene pairing; break-apart designs detect separation around a locus without necessarily identifying its partner. Probe placement determines which rearrangements can produce the expected pattern. The [FDA-hosted ALK break-apart assay labeling](https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110012C.pdf) provides an assay-specific example of flanking probes and defined rearrangement signal patterns. Its criteria apply to that assay rather than every FISH design.
Apply it
A laboratory needs to assess rearrangement of a locus with several possible partners. A validated break-apart design can address disruption of that locus, while a dual-fusion design would answer a narrower question about a particular partner pairing. A small rearrangement that does not separate the probes sufficiently may remain undetected.
Common pitfall: A break-apart result does not necessarily identify the fusion partner or expressed transcript. FISH answers the structural question defined by its probe locations and validated signal criteria.
Fluorescence In Situ Hybridization (FISH) · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
57.How do specimen quality, signal classification and counting thresholds determine FISH interpretation?
FISH scoring requires suitable nuclei, adequate hybridization and controlled background. In the [Vysis ALK Break Apart FISH Probe Kit labeling for FFPE NSCLC tissue](https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110012C.pdf), positive patterns include orange and green signals separated by at least two signal diameters, or an isolated orange signal accompanying fused and/or broken-apart signals. Fused signals alone are negative; an isolated green signal accompanying fused signals is also negative. Exclude nuclei showing only one color, weak signals or ambiguous borders. Count each eligible cell once. Initially assess 50 tumor cells: fewer than 5 positive cells is negative, more than 25 is positive, and 5–25 requires a second reader to assess 50 cells. Combine both counts; at least 15 positive cells among 100 is positive.
Apply it
The first reader finds 12 positive cells among 50, requiring the second-reader pathway. The second finds 8 among 50. The combined result is (12 + 8)/100 = 20%, meeting this labeling's final 15% threshold. Failed quality checks or fewer than 50 evaluable tumor nuclei produce an uninformative result.
Common pitfall: These signal definitions and thresholds belong to the named assay. Section truncation can cause signal loss; counting unsuitable nuclei cannot correct preparation artifacts. Do not transfer these criteria to other FISH assays.
Fluorescence In Situ Hybridization (FISH) · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
58.How does GC-MS combine separation with molecular identification?
Gas chromatography separates suitable analytes according to their behavior in a gas-phase chromatographic system. Mass spectrometry measures ions by mass-to-charge ratio, producing patterns that support identification and quantification. Retention behavior and diagnostic ion evidence must meet established method criteria against appropriate reference standards. The [USDA Pesticide Data Program analytical procedures](https://www.ams.usda.gov/sites/default/files/media/PDPDATASOP.pdf) illustrate official analytical identification and confirmation practices in food-residue testing. The [FDA Q6A guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products) also explains why a single chromatographic retention time is insufficiently specific for identification. These sources illustrate analytical principles rather than universal clinical thresholds.
Apply it
A chromatographic peak appears at the expected retention time, but its monitored ion pattern does not meet the method's identification criteria. Investigate interference or analytical failure rather than reporting the analyte solely because the peak eluted at the expected time. Use the standards, ion criteria and tolerances specified for that analyte and method.
Common pitfall: Retention time alone does not establish analyte identity. Coeluting substances and preparation effects make mass-spectral criteria and appropriate controls necessary for reliable interpretation.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
59.How should gel and capillary electrophoresis results be interpreted?
Electrophoresis separates charged molecules under an electric field. DNA generally migrates toward the positive electrode, with fragment size strongly affecting movement through a suitable separation matrix. A molecular-weight marker supports size estimation, while controls help identify expected products and contamination. Capillary systems use narrow separation channels and detector signals to resolve fragments. Loading amount and sample quality matter: overloaded, degraded or inhibited preparations can distort bands or peaks and compromise interpretation.
Apply it
A PCR lane contains a strong band at the expected size plus a smaller band also seen in the no-template control. Compare the marker and controls, then investigate the smaller product rather than counting every band as a separate target.
Common pitfall: Expected fragment size supports identity but does not prove sequence. Co-migrating products can differ in sequence, and overloaded lanes can obscure otherwise distinct fragments.
Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
60.How do extraction methods balance target recovery and inhibitor removal?
Extraction typically combines specimen disruption, nucleic-acid release, separation from unwanted material and recovery into a compatible solution. Silica or magnetic-bead workflows rely on controlled binding, washing and elution conditions. Different matrices can require distinct lysis and cleanup strategies. More concentrated eluate does not always improve sensitivity because inhibitors may also concentrate. Manual and automated methods require evidence of recovery, contamination control and compatibility with the downstream assay for each intended specimen type.
Apply it
A concentrated tissue extract inhibits amplification, while a validated dilution restores the internal control. Evaluate cleanup and the sensitivity cost of dilution rather than assuming that the extract with the greatest measured nucleic-acid concentration is the best analytical input. The [archived CDC wastewater methods](https://archive.cdc.gov/www_cdc_gov/nwss/testing.html) provide an environmental example of matrix-dependent recovery and inhibition assessment; clinical specimen performance requires its own evidence.
Common pitfall: Automation standardizes steps but does not eliminate matrix effects or carryover. A method validated for one specimen cannot be assumed equivalent for every other matrix.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · cms_042380.pdf · Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give Diagnostic Methods approximately half of study time, including PCR interpretation, validation, sequencing, arrays, FISH and the additional techniques explicitly listed by AMT.
- Distinguish what each control actually monitors by locating it before extraction, after extraction or within amplification.
- Practise dilution, master-mix, threshold-ratio and standard-curve calculations with units and explicit assumptions.
- Match each method to its detectable alteration classes, specimen requirements and important blind spots.
- Separate analytical detection from clinical interpretation, particularly for resistance genes, tumor findings and infectious targets.
- Review the complete official outline for competencies beyond this selective guide, including applicable laboratory requirements and detailed method operation.
A practical preparation plan
1. Map study time to the four work areas
Create a competency checklist from the official outline. Allocate study effort approximately 18%, 20%, 10% and 52% across the domains, then increase time for demonstrated weaknesses without neglecting smaller domains.
2. Trace the specimen through the laboratory
For a DNA assay and an RNA assay, explain identification, preservation, extraction, clean workflow, controls, amplification and reporting. At each stage, identify one failure mechanism and the evidence that could reveal it.
3. Build a method-selection comparison
Compare targeted PCR, sequencing, copy-number arrays, SNP arrays and FISH by target, detectable alteration, specimen needs and limitations. Include GC-MS and electrophoresis because AMT explicitly lists them.
4. Calculate before interpreting
Work dilution factors, final reagent concentrations, master-mix quantities and quantitative PCR relationships. State units, final volumes, efficiency assumptions and whether software has already corrected for dilution.
5. Use errors to choose the next review task
Complete the 20 questions independently, then explain why each alternative fails. Revisit the relevant mechanism, test recall with the flashcards and use the official outline to identify remaining gaps rather than treating the drill score as a pass prediction.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Get Certified with AMT
- Molecular Diagnostics Technologist (MDT) Certification Competencies and Examination Specifications
- Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
- False-Positive Investigation Toolkit
- Real-Time qRT-PCR
- Laboratory Testing for Methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA)
- Deoxyribonucleic Acid (DNA)
- Mutation
- Fluorescence In Situ Hybridization (FISH)
- Chromosome Abnormalities Fact Sheet
- Wastewater Surveillance Testing Methods
- Characterizing sensitivity and coverage of clinical WGS as a diagnostic test for genetic disorders
- Can I add bleach to the sample preparation waste?
- cms_042380.pdf
- MAN0012618_Guidelines_Primer_Design_UG.pdf
- Client Challenge
- Deletion-Insertion - HGVS Nomenclature
- Federal Register :: Request Access
- AMTCandidateHandbook.pdf
- Federal Register :: Request Access
- Federal Register :: Request Access
- Laboratory Developed Tests | FDA
- 37032427.pdf
- Chronic Myeloid Leukemia Treatment (PDQ®) - NCI
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.